UB
IONS icon

UMB Bank’s Ionis Pharmaceuticals IONS Stock Holding History

UMB Bank’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
245
+30
+14% +$2.26K ﹤0.01% 1679
2026
Q1 		$16.1K Buy
215
+1
+0.5% +$79 ﹤0.01% 1673
2025
Q4 		$16.9K Buy
214
+14
+7% +$1.05K ﹤0.01% 1617
2025
Q3 		$13.1K Buy
+200
New +$9.77K ﹤0.01% 1576
2025
Q2 		– Sell
-6
Closed -$181 – 2159
2025
Q1 		$181 Buy
+6
New +$196 ﹤0.01% 2085
2023
Q4 		– Sell
-101
Closed -$4.58K – 1674
2023
Q3 		$4.58K Hold
101
– – ﹤0.01% 1433
2023
Q2 		$4.14K Hold
101
– – ﹤0.01% 1440
2023
Q1 		$3.61K Hold
101
– – ﹤0.01% 1461
2022
Q4 		$4K Sell
101
-13
-11% -$547 ﹤0.01% 1458
2022
Q3 		$5K Sell
114
-15
-12% -$632 ﹤0.01% 1466
2022
Q2 		$5K Sell
129
-13
-9% -$490 ﹤0.01% 1583
2022
Q1 		$5K Hold
142
– – ﹤0.01% 1657
2021
Q4 		$4K Buy
+142
New +$4.47K ﹤0.01% 1684

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

UMB Bank's IONS Position: Q2 2026 in Review

UMB Bank increased its Ionis Pharmaceuticals (IONS) stake by 14% in Q2 2026, buying an estimated $2.26K and bringing the position to 245 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

UMB Bank first reported a position in IONS in Q4 2021 and has held it in 13 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • UMB Bank held 245 shares of Ionis Pharmaceuticals worth $19.4K as of Q2 2026.
  • UMB Bank bought 30 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.26K.
  • Ionis Pharmaceuticals made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1679 holding.
  • UMB Bank first reported a position in Ionis Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.